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 Identification of Acute HIV Infection (AHI) has direct implications for the safety of blood products, 
HIV prevention, due to patient high infectiousness and HIV treatment. Antiretroviral therapy at this stage 
allows for potential immunological and viral advantages and latent reservoirs reduction [1]. Recently 
published CDC recommendations for HIV testing suggest that 4th generation (4thG) immunoassays (IAs) for 
the combined detection of HIV p24-antigen and HIV-antibody should become the standard of care for HIV 
testing because they are more sensitive than 3rd generation assays [2,3]. The same guidelines suggest  that 
confirmation of HIV screening reactivity should be assessed by the detection of viral genome (HIV-RNA) 
instead with Western Blot (WB) due to the significant less sensitivity of WB in the early stages of HIV 
infection. In contrast to other 4thG  IAs, a recently CE approved  HIV assay, the LIAISON-XL Murex HIV 
Ab/Ag (DiaSorin, Saluggia, Italy) offers the advantage of a signal discrimination between HIV-p24 and 
HIV-antibody reactivity.  
 In the year 2013, at the laboratory of Microbiology and Virology, Infectious Diseases Department, 
University of Torino, Italy, 15,412 HIV tests were routinely performed (HIV infection rate: 1.8%), with the 
following procedure: HIV screening with 4thG ARCHITECT HIV Ag/Ab Combo (Abbott Diagnostics, 
Rome, I), re-testing reactive samples with LIAISON-XL, confirmation of screening results with WB (HIV-1, 
BIO-RAD, Milan, I) and/or HIV-RNA (CAP/CTM HIV-1, v2.0, Roche Molecular Diagnostic, Branchburg, 
NJ, USA). ARCHITECT and LIAISON-XL analytical sensitivity according to WHO p24 (NIBSC 90/636) 
and French National Reference (SFTS 2007) HIV standards is 17.8 and 22 pg/ml, respectively (1.032 and 
0.873 IU/ml) [4]. Following latest CDC recommendations, we reviewed AHI identified in the year 2013 (15 
patients, corresponding to 5.4% of new HIV infections) defined by a positive HIV-RNA and a non-
reactive/indeterminate WB [1].   
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 The two 4thG IAs correctly identified AHI infection in all patients (average age: 40 years ± 11; 
CD4+ cell count: 477 ± 209/uL; HIV-RNA median level: 942,295, range 95,295 - >10 million copies/mL). 
By LIAISON-XL HIV-antibodies and  p24 were positive in 10/15  and 11/15 AHI, respectively (sensitivity: 
67 and 73%). Fiebig stage II and III  [5] were identified in 5/5 and 3/3 patients (HIV-RNA > 500,000 and > 
300,000 copies/mL, respectively). WB was negative in Fiebig stage II and III patients (n=8) and 
indeterminate in Fiebig stage IV (7 patients) (Table 1). p24 correlation with HIV-RNA was good (r=0.822, 
p=0.0002, 95% CI 0.535-0.939).  
 In conclusion, 4thG IAs  are very sensitive for the detection of AHI and they enhance the early 
detection of  HIV infection during the acute phase, when substantial HIV transmission occurs, thus 
representing an important advance in HIV testing to  address HIV public health burden. Confirmation of 
their results should not  include WB, but the detection of HIV-RNA due to the lack of WB sensitivity  in the 
early stages of HIV infection. Recently commercialized 4thG IAs allowing signal discrimination between 
reactivity due to p24 and HIV antibody offer the advantage of a better classification of AHI. This is certainly 
an added value in situations where HIV-RNA testing is not available.  
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Table 1 
Characteristics of the 15 patients with AHI. 
ID Age years Sex Risk Factor CD4/ul 
ARCHITECT 
Ag/Ab Combo 
 S/CO ratio 
LIAISON-
XL  
HIV-p24 
S/CO ratio 
LIAISON-
XL 
Antibody 
S/CO ratio 
HIV-RNA 
copies/mL 
Fiebig 
stages 
HIV 
GENOTYPE WB 
1 37 M MSM 222 1.74 2.6 160 586,295 III B Negative 
2 31 M MSM 502 1.62 Negative 25 336,000 III B Negative 
3 31 M MSM 377 2.12 2 Negative 502,802 II B Negative 
4 50 M MSM 561 41 Negative 56 301,154 IV Na IND 
5 42 M Etero/bisex 270 28.9 29 Negative 740,881 II B Negative 
6 38 F Etero/bisex 749 92 Negative 22 95,295 IV B IND 
7 40 M MSM 452 129 168 Negative >10,000,000 II B Negative 
8 37 M MSM 788 35 Negative 43 1,802,927 IV Na IND 
9 40 M MSM 447 190 105 39 >10,000,000 III B Negative 
10 45 M MSM 566 88 1.25 41 288,769 IV B IND 
11 49 M MSM 39 88 5.4 36 3,955,236 IV CRF02_AG IND 
16 69 M MSM 705 116 51 Negative >10,000,000 II A Negative 
13 25 M MSM Na 373 1.85 106 410,000 IV B IND 
14 48 M MSM 335 39 16 35 6,019,484 IV B IND 
15 28 M MSM 503 1.76 1.27 Negative 1,144,212 II Na Negative 
ARCHITECT and LIASON-XL non reactive samples for S/CO (Cut-off) ratio ≤ 1. 
IND: Indeterminate WB pattern according to CDC interpretative criteria. 
Na: Not available. 
	  
	  
